Compare BWAY & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | NPCE |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | Israel | United States |
| Employees | 129 | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 674.2M | 623.0M |
| IPO Year | N/A | 2021 |
| Metric | BWAY | NPCE |
|---|---|---|
| Price | $15.21 | $15.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $13.25 | ★ $18.33 |
| AVG Volume (30 Days) | 127.0K | ★ 196.7K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $99,986,000.00 |
| Revenue This Year | $309.69 | $0.90 |
| Revenue Next Year | $26.21 | $24.46 |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $9.98 | $7.56 |
| 52 Week High | $26.63 | $19.60 |
| Indicator | BWAY | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 41.67 |
| Support Level | $14.56 | $12.52 |
| Resistance Level | $16.63 | $17.04 |
| Average True Range (ATR) | 0.65 | 1.17 |
| MACD | -0.11 | -0.34 |
| Stochastic Oscillator | 13.24 | 24.54 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.